Wordt geladen...
Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032
PURPOSE: Previously our randomized Phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 monoclonal antibody, granulocyte macrophage-colony stimulating factor (GM-CSF), and interleukin-2 (IL2) improved survival for children with high-risk neuroblastoma that had r...
Bewaard in:
| Gepubliceerd in: | Clin Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8046731/ https://ncbi.nlm.nih.gov/pubmed/33504555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3909 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|